Abstract: The (S,S) optical isomer of a compound having the general formula ##STR1## wherein R and R.sub.1-5 are as defined herein, is recovered essentially free of the (R,S) and (S,R) isomers, by forming a solution of the esters of the (S,S) and the (R,S) and/or (S,R) isomers of said compound, selectively precipitating an acid salt (e.g. maleate) of the (S,S) ester from the solution, and treating the precipitate to form the desired free acid.

Abstract: Optical isomeric compounds having the general formula ##STR1## are prepared by: reacting by catalytic hydrogenation a compound of the formula ##STR2## with a compound of the formula ##STR3## wherein R, R.sub.1, R.sub.2 and R.sub.3 are as defined herein, to form a mixture of isomers in a ratio of L(S)L(S)>D(R)L(S); and recovering the (S,S) diastereomer by selectively precipitating an acid salt of the (S,S) ester from the solution.

Abstract: Polyene compounds represented by the general formulae ##STR1## in which: R and R.sub.1 are each hydrogen or an alkyl group of from 1 to 5 carbon atoms;R.sub.2 is an alkyl group of from 1 to 5 carbon atoms;R.sub.3 is hydroxyl, alkoxy of from 1 to 5 carbon atoms, NH.sub.2, NHR.sub.2 or NR.sub.2 R.sub.2 and Z is a cycloalkyl, cycloalkenyl or cycloalkdienyl group substituted with from 0 to 5 alkyl groups, a keto group or a hydroxyl group or a phenyl group substituted with from 0 to 4 hydroxy, alkoxy, alkyl, aryloxy, aralkyloxy or trifluoromethyl groups or halogen atoms or combinations thereof and the pharmaceutically-acceptable salts thereof.The foregoing compounds have been found to be effective in the treatment of psoriasis, inflammatory conditions and allergic responses.

Abstract: X is in the 8 position and is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n ;Y is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n ;R.sub.2 is monosubstituted or independently disubstituted H, carboxyl, or alkylcarboxy;Z is 0; andn is 0 to 10 inclusive,useful in the treatment of ischemic heart disease and hypertriglyceridemia.

Abstract: This invention relates to novel compounds having pharmaceutical activity and having the general structure ##STR1## wherein the Z, R.sub.1, R.sub.2, R.sub.3, R.sub.4, n and m are defined within.

Abstract: New quinoline compound, and the corresponding 1,2-; 1,3-; and 1,4-benzodiazines, the quinoline compounds being of the formula: ##STR1## and salts thereof, wherein R.sub.1 and R.sub.2 are independently hydrogen, lower alkyl, halo, trifluoromethyl, amino, lower alkyl amino, lower acylamino, cyano, aryl, aryl/lower alkylene, nitro, lower alkynyl, lower alkenyl, lower alkyl sulfinyl, lower alkyl sulfonyl, lower alkoxycarbonyl, carboxyl, lower alkoxy, lower alkanoyl, or lower alkenoyl,Y is oxygen, sulfur, nitrogen or R.sub.3 N wherein R.sub.3 is hydrogen, lower alkyl, alkenyl, alkynyl, aryl, aralkyl, acyl, aminoalkyl, or carboxyalkyl,Z is oxygen, sulfur or nitrogen,X is cyano, carbalkoxyl, carboxyl, formyloximino, tetrazolyl, carbalkoxyalkyl or carboxyalkyl, andm is 0 or 1, are useful as medicinals, especially for treatment of asthma, and/or as intermediates in the preparation of compounds useful for treating asthma.

Abstract: Substituted piperazines of the following formula ##STR1## wherein R.sub.1 is C.sub.3 -C.sub.7 alkyl; R.sub.2 is keto or hydroxy C.sub.3 -C.sub.7 alkyl, keto C.sub.4 -C.sub.8 cycloakyl, C.sub.4 -C.sub.8 cycloalkyl keto C.sub.3 -C.sub.7 alkyl and pharmaceutically acceptable acid addition salts thereof.

Abstract: Antihypertensive compounds of the formula ##STR1## where the substituents are as herein defined and where Z is alkylene, R.sub.3 is alkoxyalkyl and R.sub.4 is hydroxyalkyl.

Abstract: A pharmaceutical composition containing a therapeutically effective amount of a pyridinylimidazole 4- or 5-substituted carboxylic acid and esters thereof is provided to treat cardiovascular ailment.

Abstract: Provided are antihypertensive compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are hydrogen, alkyl, alkenyl, alkynyl, phenyl-alkyl, or cycloalkyl, and may be the same or different,m is an integer from 0 to 2 inclusive,n is an integer from 0 to 4 inclusive,M is alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, polycycloalkyl, polycycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, hetero-cycloalkyl, hetero-cycloalkyl-alkyl, fused aryl-cycloalkyl, fused aryl-cycloalkyl-alkyl, fused heteroaryl-cycloalkyl, fused heteroaryl-cycloalkyl-alkyl, alkoxyalkyl, alkylthioalkyl, alkylamino-alkyl, or dialkylaminoalkyl.Y is hydroxy, alkoxy, amino, or substituted amino, aminoalkanoyl, aryloxy, aminoalkoxy, or hydroxyalkoxy, andR.sub.7 is alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclic, ##STR2## wherein R is hydrogen, alkyl, or aryl, and where Y is hydroxy, their pharmaceutically acceptable, nontoxic alkali metal, alkaline earth metal, and amine salts.

Abstract: Compounds of the structure: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are hydrogen, alkyl, alkenyl, alkynyl, phenyl-alkyl, or cycloalkyl,n is an integer from 0 to 4 inclusive,M is heterocyclic or heterocyclic alkyl,Y is hydroxy, alkoxy, amino, or substituted amino, amino-alkanoyl, aryloxy, aminoalkoxy, or hydroxyalkoxy, andR.sub.7 is hydrogen, alkanoyl, carboxylalkanoyl, hydroxyalkanoyl, amino-alkanoyl, cyano, amidino, carbalkoxy, ZS, or ##STR2## wherein Z is hydrogen, alkyl, hydroxyalkyl, aminoalkyl or the radical ##STR3## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, M and Y are as described above; and where Y is hydroxy their nontoxic, pharmaceutically acceptable alkali metal, alkaline earth metal, and amine salts.

Abstract: New triazoloquinoxalin-1,4-diones are described as well as the use thereof as anti-allergenic agents.

Abstract: Unsaturated heterocyclic dihydropyridine of the formula ##STR1## wherein R.sub.3 and R.sub.4 together with the N to which they are attached form an unsaturated heterocyclic group, have been found to possess useful anti-hypertensive activity.

Abstract: Polyolefinic compounds represented by the general formula ##STR1## in which R and R.sub.1 are each hydrogen or an alkyl group of from 1 to 5 carbon atoms; R.sub.2 is an alkyl group of from 1 to 5 carbon atoms; R.sub.3 is hydroxyl, alkoxy of from 1 to 5 carbon atoms, NH.sub.2, NHR.sub.2 or NR.sub.2 R.sub.2 and Z is a cycloalkyl, cycloalkenyl or cycloalkdienyl group substituted with from 0 to 5 alkyl groups, a keto group or a hydroxyl group or a phenyl group substituted with from 0 to 4 hydroxy, alkoxy, alkyl or trifluoromethyl groups or halogen atoms or combinations thereof and the pharmaceutically-acceptable salts thereof.The foregoing compounds have been found to be effective in the treatment of psoriasis, inflammatory conditions and allergic responses.

Abstract: N-Morpholinoalkyl dihydropyridines are purified by precipitating their acid addition salts in an acidic organic solvent, dissolving the precipitate in a two-phase solvent system and crystallizing the N-morpholinoalkyl dihydropyridines from the organic phase of the two-phase solvent system.

Abstract: The compounds of the formula: ##STR1## wherein each of the substituents is as defined herein are useful anti-hypertensive agents.

Abstract: (3S)-2-N-[(1S)-1-Ethoxycarbonyl-1-(2,3-dihydro-1H-inden-2-yl)-methyl]-L-ala nyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid is a antihypertensive agent.

Abstract: Unsaturated heterocyclic dihydropyridines of the formula: ##STR1## wherein the substituents defined herein have been found to have useful antihypertensive activity.

Abstract: Compounds of the formula ##STR1## wherein Z is alkylene containing 1 to 5 carbon atoms; R.sub.3 is aminoalkyl containing 2 to 4 carbon atoms; R.sub.4 is H, alkyl, cycloalkyl, aminoalkyl, hydroxyalkyl or alkoxyalkyl; and the remainder of the variables are as described in the specification are useful as anti-hypertensives.

Abstract: Compounds of the general formula ##STR1## and their pharmaceutically-acceptable salts, wherein the substituents are as defined herein, having antihypertensive activity.